CANY
CRVS icon

Caxton Associates (New York)’s Corvus Pharmaceuticals CRVS Stock Holding History

Caxton Associates (New York)’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-43,325
Closed -$104K – 547
2021
Q4 		$104K Buy
+43,325
New +$168K 0.01% 525

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Caxton Associates (New York)'s CRVS Position: Q1 2022 in Review

Caxton Associates (New York) sold out of Corvus Pharmaceuticals (CRVS) in Q1 2022, closing a stake of 43,325 shares — an estimated $104K sold.

Caxton Associates (New York) first reported a position in CRVS in Q4 2021 and held it in 1 quarter. The position peaked at $104K in Q4 2021. 57 funds tracked by Wall St. Rank hold CRVS as of Q1 2022.

  • Caxton Associates (New York) reported no remaining Corvus Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 43,325 Corvus Pharmaceuticals shares in Q1 2022, an estimated $104K.
  • Caxton Associates (New York) first reported a position in Corvus Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Caxton Associates (New York)'s Corvus Pharmaceuticals position peaked at $104K in Q4 2021.
  • 57 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2022.

Based on Caxton Associates (New York)'s 13F filing for Q1 2022, filed 16 May 2022.